Health Care

More | | | Editor

New drug treats advanced breast cancer

Thursday, March 28, 2013 4:57 PM
Last updated Friday, March 29, 2013 2:35 AM
  • Follow We Think Pink

Martha DeMore looked restless Thursday as she sat in the infusion room at Augusta Oncology Associates.

Back | Next
Registered nurse April Powell hooks up an IV to Martha DeMore so she can get a treatment of a cancer drug that is targeted to direct tumor sites, slowing disease progression with fewer side effects to normal cells.   EMILY ROSE BENNETT/STAFF
EMILY ROSE BENNETT/STAFF
Registered nurse April Powell hooks up an IV to Martha DeMore so she can get a treatment of a cancer drug that is targeted to direct tumor sites, slowing disease progression with fewer side effects to normal cells.

“I probably sit still longer here than I do the rest of the day,” she said jokingly as she waited for her chemotherapy to begin.

DeMore is battling a recent recurrence of her breast cancer with a new drug that is causing a buzz in breast cancer treatment circles. DeMore is the first at the practice to get Kadcyla, or ado-trastuzumab emtansine, which combines the antibody-targeted treatment Herceptin with an additional drug toxic to breast cancer cells.

“It is directed to the tumor site,” said Dr, Alice David, DeMore’s oncologist. “It is able to shrink the tumor. It is able to slow the disease progression and prolong survival as well.”

Compared to the standard treatment for those, such as David, who are no longer helped by Herceptin, it increased progression-free survival by about three months and increased overall survival by about six months, according to the Food and Drug Administration.

Pam Anderson, the program coordinator for cancer services at University Hospital, recently returned from a meeting of the National Consortium of Breast Centers.

“Every speaker mentioned this drug,” she said.

Kadcyla, which had been clinically tested under the name T-DM1, was approved by the FDA on Feb. 22, and DeMore started on it less than a week
later.

Her cancer had already spread to her liver when she was diagnosed in 2004, but after the original treatment “everything went away,” DeMore said. She stayed on Herceptin until the cancer came back a couple of months ago.

“We were waiting for the (drug) to be approved by the FDA,” DeMore said. “Dr. David was really excited and hopeful that it would be approved soon.”

David said she hopes the targeted nature of the treatment means less damage to healthy tissue and thus fewer side effects than the previous treatments.

That’s important to a patient like DeMore, who has a very active lifestyle, David said.

Though the “Herceptin did its job,” she thinks the cancer figured out a way around it and is thankful there is something new to combat it.

“It’s a good thing they keep working on it,” DeMore said.

Comments (1)

Add comment
ADVISORY: Users are solely responsible for opinions they post here and for following agreed-upon rules of civility. Posts and comments do not reflect the views of this site. Posts and comments are automatically checked for inappropriate language, but readers might find some comments offensive or inaccurate. If you believe a comment violates our rules, click the "Flag as offensive" link below the comment.
bumblebeerose
654
Points
bumblebeerose 03/29/13 - 05:56 am
0
0

Good Luck

I hope all goes well and God Bless you and your family.

Back to Top

Loading...